---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002951"
form_type: "8-K"
ticker: null
cik: "0001044378"
company_name: "BIOCEPT INC"
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:33:04.750482+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biocept explores strategic alternatives, reduces workforce by 36%, projects $13M cash

## Summary
- Commenced evaluation of strategic alternatives including acquisition, merger, asset sale; engaged EF Hutton as advisor.
- Workforce reduction of approximately 36% expected in Q1 2023; severance and related costs estimated at $0.6M.
- Projects year-end 2022 cash balance of about $13M; plans to cease COVID-19 testing at end of January 2023.
- CNSide assay remains a focus but company seeks to extend cash runway amid exploration.
- No assurance of successful strategic outcome; no further updates unless board approves a specific course.

## SEC filing metadata
- accession: 0001193125-23-002951
- form_type: 8-K
- cik: 0001044378
- company_name: BIOCEPT INC
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/0001193125-23-002951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/d423520d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002951
- JSON: https://secwatch.observer/filing/0001193125-23-002951.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002951.txt

## Key facts
- Restructurings & Charges
  BIOCEPT INC announced a restructuring with charges of approximately $0.6 million (approximately 36%).
  - Type: restructuring
  - Charge: approximately $0.6 million
  - Headcount: approximately 36%
  source text: the Company is implementing a restructuring plan that will result in a reduction in the Company’s workforce by approximately 36%. The reduction in force is expected to be completed during the first quarter of 2023. The Company estimates that it will incur charges of approximately $0.6 million for severance and other employee termination-related costs in the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000119312523002951/0001193125-23-002951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.